Close Menu


The firm's Q-plasia OncoReader Breast is the first in its line of products for different cancers, including skin, lung, and ovarian cancer.

On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.

Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.